[AMLN] Up Date .. Looks like a Negative Barrons Spin.
stockcharts.com
Investors should be cautious on Amylin - Barron's
Sun Jan 29, 2006 05:11 PM ET
NEW YORK, Jan 29 (Reuters) - Investors in Amylin Pharmaceuticals Inc. (AMLN.O: Quote, Profile, Research) should be cautious, as most of the good news about its star diabetes drug Byetta appears to be fully priced into the expensive stock, financial weekly Barron's reported.
Amylin's stock market value already exceeds $4.8 billion, or 37 times its expected 2005 sales, and much hinges on it getting U.S. approval for a once-a-week version of Byetta, Barron's said.
But regulatory delays could hurt the company, while endocrinologists at cancer centers in New York and Texas say they wish there had been research into Byetta's effect on human thyroid tissue called C-cells, Barron's said.
Still, the cancer specialists said the risk-benefit balance strongly favors Byetta, Barron's said.
© Reuters 2006. All Rights Reserved.
yahoo.reuters.com |
